H.C. Wainwright analyst Oren Livnat lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $21 from $25 and keeps a Buy rating on the shares. The company’s “light” 2025 guidance reflects shift to new oxybate patients versus switchers, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target lowered to $19 from $22 at Needham
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ
- Avadel Pharmaceuticals sees Q4 revenue $50M, consensus $52.7M
- Avadel Pharmaceuticals sees FY24 revenue $169M, consensus $171.41M